Patent Assignment
Reel/Frame 025783/0548
Security Agreement
Recorded: 2011-02-11
Received: 2011-02-11
Pages: 9
Assignor
EURAND, INCORPORATED
Executed: 2011-02-11
Assignee
BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
101 SOUTH TRYON STREET, NC1-002-15-39, CHARLOTTE, NC, 28255, UNITED STATES
Covered Properties
(48)
Banking Machine That Operates Responsive to Data Bearing Records
Application:
12/931,654 →
Rapidly Dispersing Granules, Orally Disintegrating Tablets and Methods
Application:
61/419,114 →
Ondansetron Orally Disintegrating Tablet Compositions for Prevention of Nausea and Vomiting
Application:
12/956,249 →
Compressible-Coated Pharmaceutical Compositions and Tablets and Methods of Manufacture
Application:
12/956,543 →
Diluted Pancrelipase Formulation
Application:
61/389,037 →
Orally Administered Corticosteroid Compositions
Application:
12/896,005 →
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Application:
12/872,354 →
Pancrelipase Predigested Nutritional Formula
Application:
61/371,608 →
Fexofenadine Microcapsules and Compositions Containing Them
Application:
61/354,575 →
Orally Disintegrating Tablet Compositions Comprising Combinations of Non-Opioid and Opioid Analgesics
Application:
12/772,776 →
Orally Disintegrating Tablet Compositions Comprising Combinations of High and Low-Dose Drugs
Application:
12/772,770 →
Micropellet Compositions Comprising Pancreatin-Containing Digestive Enzyme Mixtures
Application:
61/330,768 →
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
Application:
12/688,493 →
Taste Masked Topiramate Composition and an Orally Disintegrating Tablet Comprising Such
Application:
61/293,455 →
Pharmaceutical Compositions Comprising Anti-Psychotic Drugs
Application:
61/293,067 →
Controlled Release Compositions Comprising Meclizine or Related Piperazine Derivatives
Application:
61/292,084 →
Compositions Comprising Melperone
Application:
12/639,496 →
Compositions Comprising Melperone and Controlled-Release Dosage Forms
Application:
12/639,470 →
Orally Disintegrating Tablet Compositions of Lamotrigine
Application:
12/628,677 →
Preparation of Controlled Release Skeletal Muscle Relaxant Dosage Forms
Application:
12/487,339 →
Compositions Comprising Weakly Basic Drugs and Controlled-Release Dosage Forms
Application:
12/424,201 →
Orally Disintegrating Tablet Compositions of Temazepam
Application:
12/339,908 →
Orally Disintegrating Tablets Comprising Diphenhydramine
Application:
12/331,963 →
Preparation of controlled release skeletal muscle relaxant dosage forms
Application:
12/314,290 →
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Application:
12/236,723 →
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Application:
12/236,719 →
Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids
Application:
12/209,285 →
Orally Disintegrating Tablet Compositions of Lamotrigine
Application:
12/166,757 →
Pharmaceutical Compositions Comprising an Active Substance from the Substituted Benzhydrylpiperazine Family
Application:
12/057,177 →
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Application:
12/026,887 →
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Application:
12/026,882 →
Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
Application:
11/847,219 →
Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids
Application:
11/668,408 →
Drug Delivery Systems Comprising Weakly Basic Selective Serotonin 5-HT3 Blocking Agent and Organic Acids
Application:
11/668,167 →
Methods and Systems for Producing Ethanol Using Raw Starch and Selecting Plant Material
Application:
11/546,522 →
Timed, Sustained Release Systems for Propranolol
Application:
11/500,892 →
Taste-Masked Pharmaceutical Compositions with Gastrosoluble Pore-Formers
Application:
11/256,653 →
Taste-Masked Pharmaceutical Compositions
Application:
11/248,596 →
Orally disintegrating tablets of atomoxetine
Application:
11/223,819 →
Timed, pulsatile release systems
Application:
11/120,139 →
Modified Release Dosage Forms of Skeletal Muscle Relaxants
Application:
10/713,929 →
Timed Pulsatile Drug Delivery Systems
Application:
10/675,656 →
Controlled Release Potassium Chloride Tablets
Application:
10/619,924 →
Timed, sustained release systems for propranolol
Application:
10/453,848 →
Extended Release Dosage Forms of Propranolol Hydrochloride
Application:
10/335,295 →
Pulsatile Release Histamine H2 Antagonist Dosage Form
Application:
10/057,759 →
Timed, Sustained Release Systems for Propranolol
Application:
09/971,167 →
Timed Pulsatile Drug Delivery Systems
Application:
09/778,645 →